Cardiology

Your Article Summary

See Latest Articles

Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study)
Blood Pressure, 07/01/09

Gerdts E et al. – During systematic antihypertensive treatment in hypertensive pts with electrocardiographic left ventricular (LV) hypertrophy, lower in-treatment pulse pressure (PP) was associated with lower in-treatment LV function and cardiac output as well as higher rate of cardiovascular events

• Study of associations of in-treatment PP with LV systolic function and cardiovascular events
• Subjects: 883 pts with electrocardiographic LV hypertrophy during 4.8 yrs of randomized losartan- or atenolol-based treatment
• Echocardiographic substudy of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

• Both treatments similarly reduced PP
• In different multiple regression models, lower in-treatment PP independently associated with lower in-treatment LV ejection fraction, stress-corrected midwall shortening, stroke volume, and cardiac index
• In time-varying Cox regression models, 10 mmHg lower in-treatment PP associated with 28% higher rate of cardiovascular events
• Association independent of in-treatment LV mass and ejection fraction, history of ischemic heart disease, Framingham risk score and study treatment allocation

Today in Physiology...keeping you current

Receive free subspecialty "5-minute updates" via email

Obesity-Related Cardiorenal Syndrome
The Journal of Clinical Hypertension, 10/20/09

The Effects of Resistance Training on Metabolic Health With Weight Regain
The Journal of Clinical Hypertension, 11/04/09

Usefulness of Various Plasma Biomarkers for Diagnosis of Heart Failure in Children With Single Ventricle Physiology
The American Journal of Cardiology, 10/27/09

See All of Physiology